Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis.
about
Long-term drug treatment for obesity: a systematic and clinical reviewBrain insulin resistance in Alzheimer's disease and its potential treatment with GLP-1 analogsEfficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic reviewEvaluation and Treatment of Severe Obesity in Childhood.Liraglutide and obesity: a review of the data so far.Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.Retrospective analysis of safety and efficacy of insulin-to-liraglutide switch in Japanese type 2 diabetes: A caution against inappropriate use in patients with reduced β-cell function.The prevention and treatment of obesity.Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials.Small lipidated anti-obesity compounds derived from neuromedin U.Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes.Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes.Effects of glucagon-like peptide-1 receptor agonists on renal functionGlucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy.Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity.Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients.Liraglutide for weight management: a critical review of the evidence.Glucagon-like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective.Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials.Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association.Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials.A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients.
P2860
Q22253010-01B6E75A-1FB1-4B14-8D0B-2EC2F87A952CQ27012801-7DC5B277-A649-4133-8EEB-7FF89C48324EQ28076726-0DFA751F-8510-46D1-A39E-FDEA1E18E6D2Q30300992-D0B42DF9-EEF0-499B-86A7-FE5E7AF7C84FQ30924982-3E383BB0-5B6C-4BD4-86E1-7050B54923F2Q31167862-88E4E818-D7D9-4B70-B92D-548424B4A2CBQ33607749-E59E702C-E0FD-4439-A15D-9FE6FA0FE231Q34521259-E2253125-F57B-4457-A702-B0FC0DD73248Q35209811-1A71BECC-5399-4B15-A432-80ADDF3B4907Q35708420-D2925D77-028A-49AF-9848-DEC0F7E7F442Q36284121-7B676E1F-99B0-4BEE-BBFD-71149EF5650FQ36709118-37922610-6E85-4F86-A94B-52E3067407F7Q37232679-23841A32-6403-433E-9D8C-A66A9454B2D3Q37402786-668C98DB-E63A-4E1D-8012-97207E10EBE8Q37501257-424C1441-234E-40C1-80CF-248794654A4FQ37562586-ADAA0D70-9D87-48DF-990F-54330556FFF5Q37581317-A569ADC7-D4C8-4A9B-87F2-0AE714C8821DQ37711170-B28044BB-F147-4DD7-912D-19FF7E099DE0Q38243035-EBBEFCF9-D2B1-4DF1-A15F-8DCF6486EBBCQ43446368-9F309D4E-1B25-47CF-BF18-3E7720A4AFB0Q46637270-021C02C8-1A10-434C-B202-32BDD832E064Q47154668-72984D2D-DE31-40F9-9FC2-0306E2D18A90Q48339050-9B6C282A-D6F6-49E3-A03E-6EBEA85114F7Q51278208-90AAB04B-486D-4C75-B0AC-213CD1C8EA37
P2860
Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis.
@ast
Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis.
@en
type
label
Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis.
@ast
Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis.
@en
prefLabel
Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis.
@ast
Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis.
@en
P2093
P2860
P356
P1476
Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis.
@en
P2093
Carlo M Rotella
Edoardo Mannucci
Matteo Monami
Niccolò Marchionni
P2860
P304
P356
10.1155/2012/672658
P577
2012-05-20T00:00:00Z